Important Safety Information

• Renvela is contraindicated in patients with bowel obstruction. • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery.  View additional Important Safety Information.

Instructing Patients on How to Prepare Renvela For Oral Suspension (Powder)

How to prepare a 2.4 gram packet of Renvela powder:

1. Measure a minimum of two ounces of water into a cup.

(Note: 2 ounces = 4 tablespoons = ¼ measuring cup. Different amounts of water are needed based on the dose of Renvela powder.)

2. Open the Renvela packet by tearing or cutting it along the top and pour the entire packet into the cup of water.

3. Stir the mixture thoroughly.

(Note: The powder does not dissolve, and the mixture will be cloudy.)

4. Patients should drink the entire mixture within 30 minutes and stir vigorously just before drinking.

Remind patients to take Renvela with kidney-friendly and low-phosphorus meals.

Renvela for Oral Suspension Video

For more information about Renvela powder and how to prepare it, watch this instructional video.

View now

Contact Us

Sanofi US
500 Kendall Street
Cambridge, MA 02142

Tel: 617-252-7500
Fax: 617-252-7600
Toll free: 800-847-0069

Contact Sanofi

Indication

Renvela is indicated for the control of serum phosphorus in patients with CKD on dialysis.

Important Safety Information

  • Renvela is contraindicated in patients with bowel obstruction.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • The most frequently occurring adverse reactions in a short-term study with sevelamer carbonate tablets were nausea and vomiting.
  • In a short-term study of sevelamer carbonate powder dosed three times daily, adverse events were similar to those reported for sevelamer carbonate tablets.
  • In long-term studies with sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, the most common adverse events included vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation.
  • Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renvela tablet have been reported. Caution should be exercised in these patients and consideration given to using sevelamer suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renvela.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take Renvela with meals and to adhere to their prescribed diets.

Please see full Prescribing Information (PDF).